SellYourAIData
Get a free valuation Contact

AI Data Deal TrackerDeal brief

×

Tempus to receive $200M in data licensing and model fees under AstraZeneca and Pathos oncology model deal

Tempus, AstraZeneca and Pathos AI agreed to build a multimodal oncology foundation model trained on Tempus's de-identified cancer data. Tempus will receive $200 million in data licensing and model development fees.

CHICAGO, April 23, 2025 Tempus AI, AstraZeneca and Pathos AI announced an agreement to build a large-scale multimodal model for oncology drug discovery, with Tempus receiving $200 million in data licensing and model development fees, Pharmaceutical Technology reported.1

Terms of the deal

Tempus will contribute its de-identified oncology data library to train the model, and all three parties will share the completed model.1 The agreement is multi-year. Tempus will receive $200 million in data licensing and model development fees.1 Tempus shares rose 14.6% on April 23 following the announcement.1

Background

AstraZeneca and Tempus first partnered in 2021 on an AI-driven oncology research alliance and expanded it in 2023 to deploy Tempus Next for clinical decision support in non-small cell lung cancer.1 The model aims to surface biological and clinical insights, identify new drug targets and support new cancer therapies.

What it means for data sellers

A large, well-structured clinical dataset can anchor a nine-figure agreement when the buyer needs it to train a specialized model. Sellers should note that the structure combined cash with model access, and that it followed a long working relationship. Data that has been de-identified, linked and kept current is what turns a library into a licensable asset.

How the deal came together

  1. Three-way agreement. Tempus, AstraZeneca and Pathos AI announced a joint effort to build a large multimodal model for oncology drug discovery.
  2. Tempus supplies the data. Tempus will contribute its de-identified oncology data library to train the model.
  3. Fees to Tempus. Tempus will receive $200 million in data licensing and model development fees.
  4. Shared model. All three parties will share the completed model.

Takeaways for companies with data

  • De-identified clinical data can be licensed to train a model that the data owner also gets to use.
  • A deal can pair fees with model access, so the seller benefits from the output.
  • The relationship had been built over years, starting with a 2021 alliance.

Sources

Every numbered reference above points to an entry here. Figures come from these pages as of the date shown at the top of the article. Where a source reports a number it got from unnamed people, the text says so.

  1. AstraZeneca enters $200m AI cancer pact with Tempus and Pathos (Pharmaceutical Technology, April 2025)

###

About the AI Data Deal Tracker

SellYourAIData tracks publicly reported sales and licenses of data to AI companies, with the price, terms and sources for each. Entries are checked against public reporting and updated as deals change. SellYourAIData was not involved in this deal. To ask what your company's data could sell for, get a free valuation. To report a deal, contact us.